Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis

Neurology. 2005 Mar 8;64(5):778-9. doi: 10.1212/01.WNL.0000153532.80277.21.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Age Factors
  • Aging / drug effects
  • Aging / physiology
  • Central Nervous System / drug effects*
  • Central Nervous System / immunology*
  • Central Nervous System / physiopathology
  • Child
  • Clinical Trials as Topic / standards
  • Clinical Trials as Topic / statistics & numerical data
  • Disease Progression
  • Drug Industry / economics
  • Drug Industry / standards
  • Drug Industry / trends
  • Glatiramer Acetate
  • Humans
  • Immunologic Factors / pharmacology*
  • Immunologic Factors / therapeutic use*
  • Interferon beta-1a
  • Interferon-beta / adverse effects
  • Interferon-beta / pharmacology
  • Interferon-beta / therapeutic use
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology*
  • Multiple Sclerosis / physiopathology
  • Peptides / pharmacology
  • Peptides / therapeutic use
  • Secondary Prevention
  • Surveys and Questionnaires / standards
  • Treatment Outcome

Substances

  • Immunologic Factors
  • Peptides
  • Glatiramer Acetate
  • Interferon-beta
  • Interferon beta-1a